mTOR inhibition in glioblastoma: requiem for a dream?

被引：12

作者：

Babak, Sam

Mason, Warren P.

机构：

[1] Princess Margaret Canc Ctr, Dept Med, Toronto, ON, Canada

[2] Univ Toronto, Toronto, ON, Canada

来源：

NEURO-ONCOLOGY | 2018年 / 20卷 / 05期

关键词：

PHASE-II; EVEROLIMUS; COMBINATION; RAPTOR;

D O I：

10.1093/neuonc/noy034

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：584 / 585

页数：2

共 9 条

[1] Primary brain tumours in adults [J].

Behin, A ;

Hoang-Xuan, K ;

Carpentier, AF ;

Delattre, JY .

LANCET, 2003, 361 (9354) :323-331

[2] A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913 [J].

Chinnaiyan, Prakash ;

Won, Minhee ;

Wen, Patrick Y. ;

Rojiani, Amyn M. ;

Werner-Wasik, Maria ;

Shih, Helen A. ;

Ashby, Lynn S. ;

Yu, Hsiang-Hsuan Michael ;

Stieber, Volker W. ;

Malone, Shawn C. ;

Fiveash, John B. ;

Mohile, Nimish A. ;

Ahluwalia, Manmeet S. ;

Wendland, Merideth M. ;

Stella, Philip J. ;

Kee, Andrew Y. ;

Mehta, Minesh P. .

NEURO-ONCOLOGY, 2018, 20 (05) :666-673

[3] RTOG 0913: A Phase 1 Study of Daily Everolimus (RAD001) in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma [J].

Chinnaiyan, Prakash ;

Won, Minhee ;

Wen, Patrick Y. ;

Rojiani, Amyn M. ;

Wendland, Merideth ;

Dipetrillo, Thomas A. ;

Corn, Benjamin W. ;

Mehta, Minesh P. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 86 (05) :880-884

[4] Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study [J].

Galanis, E ;

Buckner, JC ;

Maurer, MJ ;

Kreisberg, JL ;

Ballman, K ;

Boni, J ;

Peralba, JM ;

Jenkins, RB ;

Dakhil, SR ;

Morton, RF ;

Jaeckle, KA ;

Scheithauer, BW ;

Dancey, J ;

Hidalgo, M ;

Walsh, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5294-5304

[5] MTOR interacts with Raptor to form a nutrient-sensitive complex that signals to the cell growth machinery [J].

Kim, DH ;

Sarbassov, DD ;

Ali, SM ;

King, JE ;

Latek, RR ;

Erdjument-Bromage, H ;

Tempst, P ;

Sabatini, DM .

CELL, 2002, 110 (02) :163-175

[6] A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM) [J].

Kreisl, Teri N. ;

Lassman, Andrew B. ;

Mischel, Paul S. ;

Rosen, Neal ;

Scher, Howard I. ;

Teruya-Feldstein, Julie ;

Shaffer, David ;

Lis, Eric ;

Abrey, Lauren E. .

JOURNAL OF NEURO-ONCOLOGY, 2009, 92 (01) :99-105

[7] Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials [J].

Mander, A. P. ;

Thompson, S. G. .

CONTEMPORARY CLINICAL TRIALS, 2010, 31 (06) :572-578

[8] Gene expression profiling and genetic markers in glioblastoma survival [J].

Rich, JN ;

Hans, C ;

Jones, B ;

Iversen, ES ;

McLendon, RE ;

Rasheed, BA ;

Dobra, A ;

Dressman, HK ;

Bigner, DD ;

Nevins, JR ;

West, M .

CANCER RESEARCH, 2005, 65 (10) :4051-4058

[9] Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton [J].

Sarbassov, DD ;

Ali, SM ;

Kim, DH ;

Guertin, DA ;

Latek, RR ;

Erdjument-Bromage, H ;

Tempst, P ;

Sabatini, DM .

CURRENT BIOLOGY, 2004, 14 (14) :1296-1302

← 1 →